SELLAS Life Sciences (SLS): why I’m bullish on GPS and watching ASH in December
SELLAS is developing GPS, a WT1-targeting cancer vaccine for AML in remission, with strong signs of durable benefit (physicians requesting extended treatment into year 3) and a Phase 3 survival analysis approaching its 80-death trigger. A second program, SLS009, showed 46% ORR in difficult-to-treat patients, with Q4 2026 data potentially adding value; the bullish case is 4-9x upside contingent on positive REGAL results and successful SLS009 development.
At post $11.65·Now $11.39-2.2% since postedas of Oct 23, 12:00 PM ET
1d—
3d+2.4%
1w-14.3%
1m—
3m—
6m—
1y—
Million dollar SLS yolo (two slides)
Author has held conviction in SLS since December 8th based on belief in the company's science and continues buying dips ahead of data catalysts. The position has grown to near $1M, demonstrating sustained conviction.
At post $10.84·Now $11.39+5.1% since postedas of Oct 23, 12:00 PM ET
1d—
3d-6.9%
1w-7.6%
1m+32.3%
3m+6.5%
6m—
1y—
“holding until 1 mil”
SLS holding until I have 1 mil. Thoughts
Author is holding SLS stock with conviction until reaching $1M in gains, indicating a bullish directional view and long-term commitment to the position.
At post $15.45·Now $11.39-26.3% since postedas of Oct 23, 12:00 PM ET
1d—
3d-14.1%
1w-3.0%
1m-34.7%
3m-24.9%
6m—
1y—
Here is what can still fail the SLS trial when success seems "guaranteed"
Author, a biomedicine professor, models the SLS trial using conservative Weibull methodology and estimates an 80% probability of success, 15% narrow miss, and 5% failure. Despite not being mathematically guaranteed, the expected upside from trial success and potential regulatory approvals justify current valuation; author holds 1799 shares.
At post $8.33·Now $11.39+36.7% since postedas of Oct 23, 12:00 PM ET
1d-1.7%
3d-1.2%
1w-7.8%
1m+79.8%
3m+60.1%
6m—
1y—
Space is the place, man
SLS is positioned for very positive trial readout results in the coming months with 78 of 80 events reached. Author expects positive results and a potential buyout within the next year.
At post $7.78·Now $11.39+46.4% since postedas of Oct 23, 12:00 PM ET
1d—
3d—
1w+19.7%
1m+3.5%
3m+72.2%
6m—
1y—
“full port, mix of call options with varying expirations (referenced leaps and closer-dated positions, screenshot shown but specific strikes/dates not legible in text)”
All in on cancer $SLS
SLS's GPS drug REGAL trial is near completion (78/80 events) and the author expects a positive outcome based on strong Phase 2 CR2 AML data showing 16.3 months vs 5.4 months median overall survival. Author is fully committed to the position, betting the trial success will drive stock sharply higher.
At post $8.97·Now $11.39+27.0% since postedas of Oct 23, 12:00 PM ET
1d-15.7%
3d-13.3%
1w-4.3%
1m-10.3%
3m+46.0%
6m—
1y—
“LEAPS”
Options changed my life pt.5
SLS offers a high-risk, high-reward opportunity with potential 20x upside using LEAPS, representing a speculative bet on the company's success with binary outcome.
At post $5.01·Now $11.39+127.3% since postedas of Oct 23, 12:00 PM ET
1d—
3d+4.8%
1w+41.3%
1m+64.3%
3m+133.5%
6m—
1y—
“Owns 809K shares and is continuously accumulating every week”
$SLS (Deepest Due Diligence for SLS-009, Machine Learning Models and Results, and Buyout Deep DD) (From a Deep Value Investor)
Author's 16-model ML ensemble predicts SLS-009 (Tambiciclib) will achieve 64.4% ORR and 61.1% CR/CRi in the IMPACT-AML Phase 2B trial, far exceeding the FDA's 17% CR/CRi bar for accelerated approval in AML. Combined with GPS's >99% REGAL Phase 3 success probability, SLS owns the complete AML treatment journey (induction + maintenance), creating substantial acquisition value.
At post $5.04·Now $11.39+126.0% since postedas of Oct 23, 12:00 PM ET
1d-1.8%
3d-5.6%
1w-0.8%
1m-2.2%
3m+53.4%
6m+129.2%
1y—
Long 805,000 shares of SLS
$SLS Part 2 and FINAL (Deepest Due Diligence for REGAL Trial) (From a Deep Value Investor) (Predicting BAT mOS from Predictive Model)
Author's statistical model predicts BAT median OS of 11.4 months with 99% accuracy, implying the REGAL trial will crush the 0.636 hazard ratio threshold with expected topline Cox HR of 0.35-0.50 and 99.9% posterior success probability. GPS vaccine is positioned to become the standard of care in AML CR2 if BAT mOS stays below 16-20 months. Author owns 805K shares and views SLS as a rare asymmetric opportunity with insane margin of safety.
At post $4.04·Now $11.39+181.9% since postedas of Oct 23, 12:00 PM ET
1d+2.7%
3d+2.7%
1w+21.8%
1m+17.8%
3m+122.0%
6m+224.3%
1y—
“805K shares, continuously accumulating every week”
$SLS (Deepest Due Diligence for REGAL Trial) (From a Deep Value Investor)
SELLAS Life Sciences' GPS vaccine in the REGAL Phase 3 trial for AML patients in second remission shows a deceleration in event rates (only 12 deaths in 12 months from 66 at-risk patients) that indicates a cure-fraction model. The author's model predicts a 42-48% cure fraction and hazard ratio of 0.35-0.50 (well below the 0.636 trial threshold), positioning GPS as a monopoly standard-of-care treatment for 5-8 years.
At post $3.66·Now $11.39+211.2% since postedas of Oct 23, 12:00 PM ET
1d—
3d+3.6%
1w+13.4%
1m+37.7%
3m+93.4%
6m+249.2%
1y—
SELLAS Life Sciences (SLS) - Deep Dive DD on GPS and the REGAL trial
Author has conducted comprehensive research on Sellas Life Sciences (SLS), focusing on GPS technology and the REGAL trial. The post presents an in-depth DD article arguing the investment case, though specific catalysts and price targets are not detailed in the Reddit post itself.
At post $3.81·Now $11.39+199.0% since postedas of Oct 23, 12:00 PM ET
1d—
3d-1.3%
1w-5.8%
1m+56.4%
3m+31.5%
6m+207.1%
1y—
DD: SLS to $100+: The "New Math" Moonshot
SELLAS' GPS platform is positioned for a Phase 3 REGAL trial superiority stop in early 2026, driven by delayed event rates and the FDA's new Bayesian methodology guidance. Combined with M&A tailwinds (Merck's patent cliff and bolt-on acquisition strategy) and a high short-squeeze profile, the stock is expected to reach $100+ per share on acquisition.
At post $4.40·Now $11.39+158.9% since postedas of Oct 23, 12:00 PM ET
1d-9.8%
3d-14.3%
1w-5.5%
1m+11.8%
3m+10.9%
6m+157.3%
1y—
$SLSr/pennystocks🚩SUSPICIOUS POST🚩bullish u/Yung_Ceejay · 286d ago1 prior · 50% at 3mo SLS - hype, manipulation, lies, schemes…
SLS is being manipulated by hedge funds and short sellers through coordinated naked shorting around positive catalysts, but the recent prolonged survival data is genuine and institutional ownership is rising, suggesting the shorts are in trouble and the stock will eventually recover as the truth emerges.
At post $4.11·Now $11.39+177.1% since postedas of Oct 23, 12:00 PM ET
1d—
3d0.0%
1w-3.2%
1m-8.5%
3m+15.8%
6m+210.5%
1y—
SLS Part II – Follow-up: from “discounted entry” to early re-rating (and we are still early)
SELLAS is undergoing structural re-rating driven by two clinical programs: REGAL Phase 3 approaching completion with trial metrics suggesting prolonged survival in AML maintenance, and SLS009 showing strong Phase 2 data in difficult-to-treat AML. The combination positions SELLAS as a platform oncology company rather than a single-asset binary biotech, with clean capital structure and runway into 2027, making current valuations justified by improving fundamentals rather than speculation.
At post $5.00·Now $11.39+127.8% since postedas of Oct 23, 12:00 PM ET
1d-18.0%
3d-22.8%
1w-17.8%
1m-23.6%
3m-17.4%
6m+199.6%
1y—
$SLSr/pennystocks🚩SUSPICIOUS POST🚩bullish u/Yung_Ceejay · 296d ago1 prior · 50% at 3mo Sellas Lifesciences - Cancer Moonshot in the process of squeezing! Hand written DD!
Sellas Life Sciences has two first-in-class cancer drugs (Galinpepimut-S and Tambiciclib) with strong clinical survival data in acute myeloid leukemia. Interim REGAL trial results show unprecedented median survival exceeding 13.5 months versus expected 8 months, significantly de-risking the phase 3 pivotal trial and positioning the company for rapid expansion into multiple cancer indications and potential acquisition by big pharma facing patent cliffs.
At post $4.35·Now $11.39+161.8% since postedas of Oct 23, 12:00 PM ET
1d—
3d—
1w-11.3%
1m-13.3%
3m-3.2%
6m+239.3%
1y—
SELLAS Life Sciences (SLS): A Late-Stage Biotech Entering the Final Phase and the Market Is Starting to Notice
SELLAS is a late-stage oncology biotech with a pivotal Phase 3 survival trial (REGAL) nearing completion at 72 of 80 required events in high-unmet-need AML. Clinical and strategic signals—including clean safety profile, insider buying, slowing event rates, and JPMorgan-facilitated discussions—suggest substantial upside if GPS succeeds, with valuations potentially 5-15 billion dollars on 215-217M diluted shares, versus current 525M market cap.
At post $3.31·Now $11.39+244.1% since postedas of Oct 23, 12:00 PM ET
1d+13.9%
3d+31.4%
1w+23.9%
1m+17.5%
3m+21.1%
6m+274.3%
1y—
$SLS on the verge of a massive break out
Biotech with phase 3 results pending this month for an AML immunotherapy vaccine targeting WT1. Positive interim data shows 13.5-month median survival; current market cap of $300M could expand to $4-6B if approved, supported by strong institutional ownership and insider buying.
At post $2.11·Now $11.39+439.8% since postedas of Oct 23, 12:00 PM ET
1d+10.9%
3d+11.8%
1w+34.6%
1m+88.6%
3m+138.9%
6m+266.4%
1y—
$SLSr/pennystocksStock Infobullish u/julet0790 · 318d agono track record yet “holding very large position”
Sellas $sls
Sellas Life Sciences is showing strong Phase 2 data for SLS009 in relapsed blood cancers (46% response rate, 58% in prior-therapy patients, median survival 8.9 months vs. 2.5 months baseline). Upcoming Phase 3 trials in newly diagnosed patients and final GPS Phase 3 results by year-end represent significant catalysts for a potential multi-fold gain.
At post $1.90·Now $11.39+499.5% since postedas of Oct 23, 12:00 PM ET
1d+3.2%
3d+6.8%
1w+15.8%
1m+103.2%
3m+213.7%
6m+333.2%
1y—
$SLS Is The Best Stock For Monday, Here's Why:
SELLAS has a strengthened pipeline with GPS in pivotal Phase 3 and SLS009 showing strong Phase 2 data in AML. Upcoming clinical readouts through December, broad market potential, and improved cash runway position the company for a major upside move.
At post $1.82·Now $11.39+525.8% since postedas of Oct 23, 12:00 PM ET
1d—
3d+7.7%
1w+11.5%
1m+125.3%
3m+203.8%
6m+352.2%
1y—
$SLSr/pennystocksDDbullish u/ysh1324 · 322d agono track record yet SLS ($1.75) - Phase 3 AML Trial Readout by Year-End: Hype Building for a Potential 4x-5x Runner? Full DD on Sellas Life Sciences
Sellas Life Sciences is advancing two AML therapies with near-term catalysts: Phase 2 SLS009 combo data at ASH Conference this week and Phase 3 REGAL GPS vaccine survival readout due by year-end. Positive Phase 3 data would likely trigger FDA filing and substantial stock appreciation.
At post $1.82·Now $11.39+525.8% since postedas of Oct 23, 12:00 PM ET
1d—
3d+4.4%
1w+11.5%
1m+174.7%
3m+203.8%
6m+396.7%
1y—